Clinical Trials Browser

Breast Neoplasms

NCT03449108 2025-11-21

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT03546686 2025-10-27

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

Phase 2 Recruiting

80 enrolled

Breast

Breast Neoplasms

NCT03650894 2025-03-10

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Phase 2 Active not recruiting

30 enrolled

Breast

Breast Neoplasms

NCT03409198 2024-10-15

ICON

Phase 2 Completed

82 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT06342037 2024-09-19

TONIC-3

Phase 2 Recruiting

60 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03815890 2024-05-30

BELLINI

Phase 2 Recruiting

80 enrolled

Breast

Breast Neoplasms

NCT03818685 2024-02-12

BreastImmune03

Phase 2 Unknown

95 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT04434560 2022-07-26

Neoadjuvant Immunotherapy in Brain Metastases

Phase 2 Terminated

1 enrolled 7 charts

BreastCNSDermatologicGenitourinaryGynecologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03342417 2021-11-09

Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients

Phase 2 Terminated

5 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT02892734 2020-07-16

Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

Phase 2 Terminated

3 enrolled 11 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00083278 2012-04-27

Study of MDX-010 in Stage IV Breast Cancer

Phase 2 Completed

33 enrolled

Breast

Adenocarcinoma, Breast Neoplasms

Clinical Trials

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

ICON

TONIC-3

BELLINI

BreastImmune03

ROME

Neoadjuvant Immunotherapy in Brain Metastases

Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients

Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

Study of MDX-010 in Stage IV Breast Cancer